It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient's underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions ( 5.4) and Patient Counseling Information ( 17)] . Urogenital—Priapism [see Warnings and Precautions ( 5.6)] . 7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrates within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications ( 4.1)].7.2 Alpha-BlockersPDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology ( 12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology ( 12.2)] .7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration ( 2.4)), and Clinical Pharmacology ( 12.3)] .Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] .Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] . Administration of nitrates within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications ( 4.1)]. PDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology ( 12.2)] . PDE5 inhibitors, including tadalafil, are mild order cialis super force systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology ( 12.2)]. Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil.

Other uses for this medicine

Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-times that found in the plasma. When a drug is present in animal milk, it is likely that the drug will be present in human milk.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.8.3 Females and Males of Reproductive PotentialInfertilityMalesBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months. There have cialis 20 mg 30 pills been no studies evaluating the effect of tadalafil on fertility in men or women [see Clinical Pharmacology ( 12.2)] .8.4 Pediatric UseSafety and effectiveness of tadalafil tablets in pediatric patients have not been established.8.5 Geriatric UseOf the total number of subjects in the clinical study of tadalafil for pulmonary arterial hypertension, 28 percent were 65 and over, while 8 percent were 75 and over. No overall differences in safety were observed between subjects over 65 years of age compared to younger subjects or those over 75 years of age. No dose adjustment is warranted based on age alone; however, a greater sensitivity to medications in some older individuals should be considered.

What does TADALAFIL (Generic for ADCIRCA) look like?

[See Clinical Pharmacology ( 12.3)] .8.6 Renal ImpairmentFor patients with mild or moderate renal impairment, start tadalafil tablets at 20 mg once daily. Increase the dose to 40 mg once daily based upon individual tolerability [see Dosage and Administration ( 2.2), and Clinical Pharmacology ( 12.3)] .In patients with severe renal impairment, avoid use of tadalafil tablets because of increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis [see Clinical Pharmacology ( 12.3)] .8.7 Hepatic ImpairmentBecause of limited clinical experience in patients with mild to moderate hepatic cirrhosis (Child-Pugh Class A or B), consider a starting dose of tadalafil tablets 20 mg once daily. Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied, thus avoid use of tadalafil tablets in such patients [see Dosage and Administration ( 2.3), and Clinical Pharmacology ( 12.3)] . Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data).

For Benign Prostatic Hyperplasia

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death. Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration ( 2.4)), and Clinical Pharmacology ( 12.3)] . Tadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] . For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] . 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryLimited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically super active cialis recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Clinical ConsiderationsDisease-Associated Maternal and/or Embryo/Fetal RiskPregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.DataAnimal DataTadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€
Cialis Generic	2.5mg	10 Pills	28.51€ 27.15€
Cialis Soft Tabs	20mg	30 + 4 Pills	87.43€ 83.27€
Cialis Professional	40mg	270 + 6 Pills	898.37€ 855.59€
Cialis Generic	60mg	120 + 8 Pills	240.18€ 228.74€
Cialis Professional	40mg	90 + 2 Pills	348.59€ 331.99€
Cialis Generic	40mg	10 Pills	37.79€ 35.99€
Cialis Generic	40mg	60 + 6 Pills	130.98€ 124.74€
Cialis Generic	20mg	10 Pills	31.49€ 29.99€
Cialis Generic	2.5mg	120 + 6 Pills	128.93€ 122.79€
Cialis Generic	10mg	270 + 10 Pills	308.71€ 294.01€

In one of two perinatal/postnatal developmental studies in rats, a reduction of postnatal pup survival was observed at dose levels of 60, 200 and 1,000 mg/kg.

1.1 Pulmonary Arterial Hypertension

Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration ( 2.4)), and Clinical Pharmacology ( 12.3)] . Tadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] .

Benign prostatic hyperplasia

For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] . 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryLimited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data).The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S.

Use in children

general population, the background risk of major birth defects and miscarriage in clinically super active cialis recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Clinical ConsiderationsDisease-Associated Maternal and/or Embryo/Fetal RiskPregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.DataAnimal DataTadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC. In one of two perinatal/postnatal developmental studies in rats, a reduction of postnatal pup survival was observed at dose levels of 60, 200 and 1,000 mg/kg. The no-observed effect-level (NOEL) for developmental toxicity was 30 mg/kg, which provided maternal exposure to unbound tadalafil concentrations approximately 5 times the exposure at the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 200 mg/kg/day, which produced AUCs greater than 8 times the exposure at the MRHD. Surviving offspring had normal development and reproductive performance.8.2 LactationRisk SummaryThere are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. The no-observed effect-level (NOEL) for developmental toxicity was 30 mg/kg, which provided maternal exposure to unbound tadalafil concentrations approximately 5 times the exposure at the MRHD based on AUC.

What should I know about storage and disposal of this medication?

Signs of maternal toxicity occurred at doses greater than 200 mg/kg/day, which produced AUCs greater than 8 times the exposure at the MRHD. Surviving offspring had normal development and reproductive performance.8.2 LactationRisk SummaryThere are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Tadalafil and/or its metabolites are present in the milk of lactating rats at concentrations approximately 2.4-times that found in the plasma. When a drug is present in animal milk, it is likely that the drug will be present in human milk.The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.8.3 Females and Males of Reproductive PotentialInfertilityMalesBased on the data from 3 studies in adult males, tadalafil decreased sperm concentrations in the study of 10 mg tadalafil for 6 months and the study of 20 mg tadalafil for 9 months. There have cialis 20 mg 30 pills been no studies evaluating the effect of tadalafil on fertility in men or women [see Clinical Pharmacology ( 12.2)] .8.4 Pediatric UseSafety and effectiveness of tadalafil tablets in pediatric patients have not been established.8.5 Geriatric UseOf the total number of subjects in the clinical study of tadalafil for pulmonary arterial hypertension, 28 percent were 65 and over, while 8 percent were 75 and over.

Yellow Cialis pills are often taken 30 minutes prior to intimacy for best results.
Regular use of yellow Cialis can improve erectile function over time.
The yellow pill's profile includes a 36-hour window of effectiveness.
Cialis (yellow pill) may cause minor side effects in some users.
Safe use of yellow Cialis requires a medical consultation.
Some yellow Cialis pills are designed for daily low-dose use.
The yellow Cialis pill's vibrant color helps prevent mix-ups with other pills.
Cialis’s proprietary formula is designed for sustained blood flow support.
The yellow color is part of Cialis’s branding and quality assurance.
Yellow Cialis is not suitable for everyone and requires medical screening.
Proper storage of yellow Cialis maintains its efficacy and safety.
Use yellow Cialis responsibly, following prescribed doses and instructions.

No overall differences in safety were observed between subjects over 65 years of age compared to younger subjects or those over 75 years of age. No dose adjustment is warranted based on age alone; however, a greater sensitivity to medications in some older individuals should be considered.

The yellow Cialis pill typically has embossed markings for identification.
Do not take yellow Cialis pills with nitrates due to dangerous interactions.
Yellow Cialis can be purchased as a generic or branded medication.
The medication is generally well tolerated when used as directed.
Yellow Cialis pills should be stored in a cool, dry place away from children.
Used correctly, yellow Cialis improves erectile function significantly.
The yellow pill's design prevents counterfeiting and ensures authenticity.
Cialis, including yellow tablets, should not be taken more than once per day.
Alcohol consumption can reduce the effectiveness of yellow Cialis pills.
Health care providers tailor Cialis dosage depending on age and health status.
The yellow Cialis pill's duration of action makes it popular among users.
Yellow Cialis pills are sometimes used recreationally, which is risky.

Further information

Comparison with actions of other PDE5 inhibitors

Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology ( 12.2)] .7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration ( 2.4)), and Clinical Pharmacology ( 12.3)] .Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] .Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets [see Clinical Pharmacology ( 12.3)] .

Common side effects of tadalafil

Administration of nitrates within 48 hours after the last dose of tadalafil tablets is contraindicated [see Contraindications ( 4.1)]. PDE5 inhibitors, including tadalafil, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology ( 12.2)] . PDE5 inhibitors, including tadalafil, are mild order cialis super force systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology ( 12.2)]. Patients with severe hepatic cirrhosis (Child-Pugh Class C) have not been studied, thus avoid use of tadalafil tablets in such patients [see Dosage and Administration ( 2.3), and Clinical Pharmacology ( 12.3)] . Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed with oral administration of tadalafil to pregnant rats or mice during organogenesis at exposures 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day based on AUC (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S.

Ingredient	Amount per Dose	Purpose	Notes
Tadalafil	20 mg	Active ingredient, vasodilator	Main component for ED
Microcrystalline Cellulose	-	Filler	Binds ingredients
Magnesium Stearate	-	Excipient	Improves pill stability
Titanium Dioxide	-	Coloring agent	Provides yellow color

general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

5.3 Prolonged Erection

There are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.

Storage and Discarding

Tell your doctor if you:

Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death. Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the exposure at the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis based on AUC. There are no data on the presence of tadalafil and/or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tadalafil tablets and any potential adverse effects on the breastfed child from tadalafil tablets or from the underlying maternal condition.

Label: TADALAFIL tablet, coated